Q3 EPS Estimates for Pharming Group Boosted by HC Wainwright

Key Points

• HC Wainwright raised Pharming Group’s Q3 2026 EPS estimate to $0.45 from $0.23 and maintained a “Buy” rating with a $37 price target.
• Analyst sentiment is mixed: Pharming has a consensus “Hold” rating and an average price target of $38.67, with three Buy ratings and two Sell ratings.
• PHAR shares opened at $11.20, well below the average analyst target, while MAC Alpha Capital Management acquired approximately 3.03% of the company in the second quarter.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Investment analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Pharming Group in a research report issued to clients and investors on Thursday, October 22nd. HC Wainwright analyst J. Pantginis now expects that the company will earn $0.45 per share for the quarter, up from their prior estimate of $0.23. HC Wainwright currently has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group's current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Pharming Group's Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.45 EPS.

Other equities analysts have also issued research reports about the company. Wall Street Zen raised Pharming Group to a "hold" rating in a research report on Saturday. Weiss Ratings restated a "sell (d)" rating on shares of Pharming Group in a report on Friday, August 7th. Canaccord Genuity Group set a $38.00 target price on shares of Pharming Group in a research report on Wednesday, September 23rd. Oppenheimer reiterated an "outperform" rating on shares of Pharming Group in a research note on Thursday, July 30th. Finally, Zacks Research cut shares of Pharming Group from a "hold" rating to a "strong sell" rating in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $38.67.

Pharming Group Price Performance

Shares of PHAR stock opened at $11.20 on Monday. The stock has a market cap of $792.74 million, a price-to-earnings ratio of 93.33 and a beta of -0.05. The business's fifty day moving average is $10.67 and its 200 day moving average is $12.59. Pharming Group has a twelve month low of $9.11 and a twelve month high of $21.34. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group makes up approximately 6.0% of MAC Alpha Capital Management LP's portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming's principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.